The FDA on January 10, 2014 approved the use of MEKINIST® in combination with TAFINLAR® for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, as detected by an FDA-approved test. Both MEKINIST® and TAFINLAR® are products of GlaxoSmithKline, LLC.
Bottom Ad
Advertisement
Subscribe
